Founded on April 16, 1992, by Philippe Leboulch and Irving London, Bluebird Bio, Inc. is a biotechnology company headquartered in Somerville, Massachusetts. The company's core mission is to develop curative gene therapies for severe genetic disorders, aiming to provide patients and their families with more "bluebird days." Bluebird Bio offers gene therapies for conditions such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders, beta-thalassemia, and sickle cell disease. Their market focus is primarily within the United States.
Notable figures affiliated with Bluebird Bio include President and CEO Andrew Obenshain and CFO Chris Krawtschuk. The company has achieved significant milestones, including FDA approval for their one-time gene therapy for sickle cell disease. Bluebird Bio's key products include Zynteglo, Skysona, and Lyfgenia. Despite financial challenges, including a net income loss of $819 million in 2021, the company continues to make impactful strides in the biotechnology and pharmaceutical industries.
